Timothy P. Bradshaw, Ph.D.

Consultant, Preclinical and Clinical Trial Planning

Dr Heal is an Executive Director and co-founder of DevelRx Ltd, a consultancy company that advises pharma and biotech companies on CNS R&D. He trained as a neuroscientist and behavioural pharmacologist at the University of Oxford. After a 13-year career in academic research, he moved to the pharmaceutical industry with responsibility for CNS and metabolic drug research at Boots Pharmaceuticals and subsequently BASF Pharma. 

Thereafter for 20 years he was Director of the non-clinical CRO, RenaSci Ltd. His experience in pharmaceutical R&D encompasses the approval of 16 novel CNS drugs. Dr Heal was awarded a DSc by Kings College, London University for his substantial contribution to pharmacological research. He is a Fellow of the Royal Society of Chemistry, an Honorary Fellow of the British Pharmacological Society and a Fellow of the American College of Neuropsychopharmacology. 

David is an author of more than 200 peer-reviewed research articles, reviews and chapters published in international scientific journals and books.

Mr. Crossman is responsible for the overall management of the Company and the creation, planning and execution of business and financial strategies and corporate development activities, including capital generation.
Crossman is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 500 level companies. He has a proven track record of successfully commercializing various emerging technologies including manufacturing and industrial systems, computer software, marine bioremediation, nanotechnology and life sciences.

Mr.Crossman has assisted numerous early-stage companies to refine business strategies, commercialize new products, raise capital, license technologies, scale revenues and production, and expand into global markets. As CEO of ISOPur Fluid Technologies, Crossman led the company from product introduction to global growth with expanding applications in multiple vertical markets. Important strategic alliances were developed with Siemens, BHP, Atlas Copco, Hess, Sanwa Shoko and others, creating a platform for continued strong growth.

The value of the founding shareholders’ common stock increased more than tenfold in less than three years under Crossman’s leadership. As CFO of Otis Elevator Company – Asia Pacific Operations, Crossman evaluated, negotiated and developed acquisitions, joint ventures and major capital investments in China, Japan, Korea, India, Southeast Asia, and Australia. Mr. Crossman contributed to profit growth of 20% per year and market share gains of 1% per year in this mature multi-billion dollar operation spanning 23 countries, despite aggressive competition from large Asian conglomerates. The joint ventures that he helped developed in China are among the most profitable operations of United Technologies Corp today. Bill holds a BS degree from the U.S. Merchant Marine Academy at Kings Point and a MBA from the Haas School of Business at the University of California – Berkeley.